Imatinib CAS 152459-95-5

Product Description:

Product Name: imatinib CAS NO: 152459-95-5

Synonyms:

UNII-BKJ8M8G5HI;

STI571;

Chemical & Physical Properties:

Appearance: Off-white powder

Assay: ≥99.0%

Density: 1.255g/cm3

Boiling Point: 754.9℃ at 760 mmHg

Melting Point: 113℃

Flash Point: 410.3℃

Vapor Pressure: 6.03E-24mmHg at 25℃

Safety Information:

Hazard Codes: T; N

Hazard Class: 6.1

HS Code: 2933990090

Packing Group; II

WGK Germany: 3

Safety Statements: S28; S36/37; S45

RIDADR: UN 1662 6.1/PG 2

Risk Statements: R23/24/25; R40; R48/23/24; R51/53

Imatinib is a kind of oral drugs used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. CML is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months.

Imatinib is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.